Cardiology

Study looks at the association between diuretic treatment, hyponatremia, and osteoporotic fracture risk.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the SHIFT study's value for cardiologists over various recent heart failure trials.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the factors cardiologists consider in selecting specific beta blockers for heart failure patients.

Data from the PARTNER cohort A trial show transcatheter aortic valve replacement produces similar mortality rates at one year compared with the standard procedure.

Results from the CORONARY trial show no significant difference at one year between patients with CAD who underwent on-pump vs. off-pump CABG.

Results from the ASTRONAUT trial show that adding aliskiren to standard therapy for chronic heart failure does not improve mortality or rehospitalization rates.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.

Study results presented at ACC.13 show that patients with unprotected left main coronary artery disease treated with double kissing crush stenting experienced fewer cases of restenosis and other major adverse events compared to patients who received culotte stenting.

Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.

Results from the PARTNER II trial show improvements in 30-day mortality and stroke rates in patients with aortic stenosis who are not surgical candidates who were treated using a newer version of the Sapien transcatheter aortic valve replacement system.

Landmark study results presented at ACC.13 reveal patients with vascular disease treated with niacin therapy face increased risk of myopathy and other adverse events.

Results of the ARMYDA-9 CAROTID trial indicate that loading with 600 mg clopidogrel and high-dose atorvastatin in carotid stent patients independently result in improved neurological outcomes.

Study results presented at ACC.13, the 62nd Annual Scientific Session & Expo of the American College of Cardiology, reveal that in selected STEMI patients, deferred stenting may reduce no-reflow and thrombotic events compared with immediate stenting.

Though two new blood clot removal devices only recently received FDA approval for clinical use, specialists at the Stony Brook University Cerebrovascular and Stroke Center have already seen improved outcomes in acute ischemic stroke patients after performing endovascular treatments with both advanced technologies.

Bioengineers at the University of California, San Diego have deemed a new injectable hydrogel safe and effective for repairing tissue damage caused by myocardial infarction, providing a platform to bring the gel to clinical trials within the next year.

After finding abnormal elevations of cardiac inflammation in patients with depressive illness (DI), a psychiatrist at Loyola University Medical Center, in Maywood, Ill., has proposed a new subspecialty to diagnose and treat patients with both depression and cardiovascular disease (CVD).

A roundup of recently published articles on the assessment, diagnosis, and management of hyponatremia in a variety of patient populations and clinical settings.

Research into prognostic models that focus on serum sodium levels in an effort to identify patients awaiting liver transplant who may be at higher risk of poor outcomes have been inconclusive.